Bevacizumab, a monoclonal antibody that inhibits angiogenesis by neutralizing Vascular Endothelial Growth Factor A (VEGF-A), improves PFS for GBM and is FDA approved for this common primary brain tumor1,2. The gene discussed is VEGFA; the disease is glioblastoma.